PA8469001A1 - Combinaciones de estatina-inhibidor de mmp. - Google Patents

Combinaciones de estatina-inhibidor de mmp.

Info

Publication number
PA8469001A1
PA8469001A1 PA19998469001A PA8469001A PA8469001A1 PA 8469001 A1 PA8469001 A1 PA 8469001A1 PA 19998469001 A PA19998469001 A PA 19998469001A PA 8469001 A PA8469001 A PA 8469001A PA 8469001 A1 PA8469001 A1 PA 8469001A1
Authority
PA
Panama
Prior art keywords
statin
mmp
inhibitor combinations
inhibitor
combinations
Prior art date
Application number
PA19998469001A
Other languages
English (en)
Inventor
Bruce David Roth
Roger Schofield Newton
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8469001A1 publication Critical patent/PA8469001A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCION ES UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE MMP Y UNA ESTATINA, DICHA COMPOSICION ES UTIL PARA TRATAR ENFERMEDADES VASCULARES.
PA19998469001A 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp. PA8469001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
PA8469001A1 true PA8469001A1 (es) 2002-09-17

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998469001A PA8469001A1 (es) 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp.

Country Status (18)

Country Link
EP (1) EP1063991A1 (es)
JP (1) JP2002506818A (es)
KR (1) KR20010041916A (es)
AR (1) AR018113A1 (es)
AU (1) AU1591699A (es)
BR (1) BR9815745A (es)
CA (1) CA2309588A1 (es)
CO (1) CO5070670A1 (es)
GT (1) GT199900039A (es)
HN (1) HN1999000029A (es)
MY (1) MY140504A (es)
NZ (1) NZ505994A (es)
PA (1) PA8469001A1 (es)
PE (1) PE20000348A1 (es)
SV (1) SV1999000026A (es)
UY (1) UY25436A1 (es)
WO (1) WO1999047138A1 (es)
ZA (1) ZA992106B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
CA2590278A1 (en) 2004-12-15 2006-06-22 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US20110182851A1 (en) * 2008-07-11 2011-07-28 Jan Nilsson Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE348607T1 (de) * 1995-11-02 2007-01-15 Warner Lambert Co Verfahren und pharmazeutische zusammensetzung zur regelung der lipidkonzentration
JP2000511175A (ja) * 1996-05-17 2000-08-29 ワーナー―ランバート・コンパニー ビフェニルスルホンアミドマトリックスメタロプロテイナーゼ阻害剤
NZ334897A (en) * 1996-12-09 2001-02-23 Warner Lambert Co Medicaments for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
GT199900039A (es) 2000-09-06
HN1999000029A (es) 1999-09-29
AU1591699A (en) 1999-10-11
CA2309588A1 (en) 1999-09-23
MY140504A (en) 2009-12-31
NZ505994A (en) 2003-10-31
CO5070670A1 (es) 2001-08-28
ZA992106B (en) 1999-09-30
WO1999047138A1 (en) 1999-09-23
UY25436A1 (es) 2001-10-25
SV1999000026A (es) 2000-01-18
JP2002506818A (ja) 2002-03-05
BR9815745A (pt) 2000-11-14
PE20000348A1 (es) 2000-05-22
EP1063991A1 (en) 2001-01-03
KR20010041916A (ko) 2001-05-25
AR018113A1 (es) 2001-10-31

Similar Documents

Publication Publication Date Title
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
ES2161548T3 (es) Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa.
ES2176755T3 (es) Derivados anticonvulsivos utiles para el tratamiento de la esclerosis lateral amiotrofica.
HN2003000227A (es) Inhibidores de quinasas
GT200100156A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester.
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
PT1105122E (pt) Composicoes farmaceuticas que contem inibidores de lipase
ES2178298T3 (es) Compuestos anti-inflamatorios.
UY25714A1 (es) Método para tratar ateroesclerosis empleando un inhibidor de ap2 y combinación.
ES2182874T3 (es) Procedimiento de tratamiento de las uñas.
ES2184340T3 (es) Combinaciones de inhibidores de la enzima de conversion de la angiotensina e inhibidores de la enzima metaloproteinasa matricial.
PT1032414E (pt) Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
MEP64008A (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU2003296807A1 (en) Cosmetic composition comprising a metalloproteinase inhibitor and a lipopeptide
AR015837A1 (es) Metodo de transformacion de plantas.
CU20000140A7 (es) Combinaciones de estatina-carboxialquileter
MA26486A1 (fr) Aryl- et heteroaryl-thiazolocetohydrazides inhibiteurs de proteases, et compositions pharmaceutiques les contenant .
HN2003000071A (es) Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2
PA8469001A1 (es) Combinaciones de estatina-inhibidor de mmp.
ES2132539T3 (es) Composiciones insecticidas sinergicas.
BR9808923B1 (pt) processos para fazer compostos inibidores de ciclooxigenase-2, e, compostos intermediÁrios para fazer inibidores de ciclooxigenase-2.
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
GT200200244A (es) Composicion intensiva de herbicida